

Special Issue

Lymphomas: Current Approaches and Future Perspectives towards More Personalized Treatments

Message from the Guest Editors

Lymphomas are one of the most prevalent types of cancer and the most frequently occurring of all hematological tumors. Individual aberrations as well as sets of recurrently aberrant genes are characteristic of certain lymphomas and can distinguish specific subtypes of lymphomas with different clinical outcomes and therapeutic responses. Additionally, mechanisms that reduce antitumor immunity including loss of major histocompatibility complex expression, and amplifications and rearrangements of immune checkpoint genes are also frequently observed in lymphomas. Targeted agents against lymphoma-associated proteins and immunotherapies such as antibody–drug conjugates, checkpoint inhibitors and CAR-T cells are currently the focus of efforts towards pharmacological approaches tailored to individual patients' lymphoma molecular subtype. This Special Issue of the Journal of Clinical Medicine is focused on current approaches and future perspectives towards more personalized treatments for lymphomas, with the aim of bringing together novel research findings and recent advances in this rapidly developing field.

Guest Editors

Dr. Afua Adjeiwaa Mensah

Institute of Oncology Research, Faculty of Biomedical Sciences, USI, 6500 Bellinzona, Switzerland

Dr. Patrizia Mondello

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA

Deadline for manuscript submissions

closed (25 June 2023)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



mdpi.com/si/111593

Journal of Clinical Medicine
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

[jcm](https://mdpi.com/journal/)





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



mdpi.com/journal/

[jcm](https://jcm.mdpi.com/)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).